title: ÐÑÐ¾Ð±ÐµÐ½Ð½Ð¾ÑÑÐ¸ Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´ÑÑÐ²Ð° Ð Ð¤Ð Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð° 18F Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ ÑÐ¸ÐºÐ»Ð¾ÑÑÐ¾Ð½Ð¾Ð²
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Features of the production of radiopharmaceuticals based on the radionuclide 18F using a cyclotron
Creators: name: ÐÐ°Ð»Ð¸ÑÐµ, ÐÐµÐ¾ÑÐ³Ð¸Ð¹
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: Ð Ð¤Ð (ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°Ñ)
Ð Ð (ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´)
ÐÐ­Ð¢ (Ð¿Ð¾Ð·Ð¸ÑÑÐ¾Ð½Ð½Ð¾-ÑÐ¼Ð¸ÑÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ¾Ð¼Ð¾Ð³ÑÐ°ÑÐ¸Ñ)
ÑÐ°Ð´Ð¸Ð¾Ñ Ð¸Ð¼Ð¸ÑÐµÑÐºÐ¸Ð¹ ÐºÐ¾Ð¼Ð¿Ð»ÐµÐºÑ
Ð½Ð°ÑÐ°Ð±Ð¾ÑÐºÐ°
ÑÐ¸Ð½ÑÐµÐ·
RFP (radiopharmaceutical)
RN (radionuclide)
PET (positron emission tomography)
radiochemical complex
production
synthesis

description: Ð ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÐµ Ð½Ð° ÑÐµÐ¼Ñ âÐÑÐ¾Ð±ÐµÐ½Ð½Ð¾ÑÑÐ¸ Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´ÑÑÐ²Ð° Ð Ð¤Ð Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð° 18F Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ ÑÐ¸ÐºÐ»Ð¾ÑÑÐ¾Ð½Ð°â Ð±ÑÐ»Ð¸ ÑÐ°ÑÑÐ¼Ð¾ÑÑÐµÐ½Ñ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ðµ Ð²Ð¾Ð¿ÑÐ¾ÑÑ: â¢ ÐÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð Ð¤Ð Ð¸ Ð¸Ñ ÑÐ²ÑÐ·Ñ Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð°Ð¼Ð¸, ÐºÐ»Ð°ÑÑÐ¸ÑÐ¸ÐºÐ°ÑÐ¸ÑÂ  Ð¸ Ð¾Ð±Ð»Ð°ÑÑÑ Ð¿ÑÐ¸Ð¼ÐµÐ½ÐµÐ½Ð¸Ñ. â¢ ÐÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ ÐÐ­Ð¢, ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ñ Ð´Ð»Ñ Ð¿Ð¾Ð·Ð¸ÑÑÐ¾Ð½Ð½Ð¾Ð¹ ÑÐ¼Ð¸ÑÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ ÑÐ¾Ð¼Ð¾Ð³ÑÐ°ÑÐ¸Ð¸. â¢ ÐÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ ÑÐ¸ÐºÐ»Ð¾ÑÑÐ¾Ð½Ð° Ð¸ Ð¿ÑÐ¸Ð½ÑÐ¸Ð¿ ÐµÐ³Ð¾ ÑÐ°Ð±Ð¾ÑÑ. â¢ ÐÑÐ¾Ð±ÐµÐ½Ð½Ð¾ÑÑÐ¸ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð¸Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð² Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ ÑÐ¸ÐºÐ»Ð¾ÑÑÐ¾Ð½Ð° (Ð½Ð° Ð¿ÑÐ¸Ð¼ÐµÑÐµ18F). â¢ Ð­ÑÐ°Ð¿Ñ Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´ÑÑÐ²Ð° Ð Ð¤Ð Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð° 18F (Ð½Ð° Ð¿ÑÐ¸Ð¼ÐµÑÐµ ÑÑÐ¾ÑÐ´ÐµÐ·Ð¾ÐºÑÐ¸Ð³Ð»ÑÐºÐ¾Ð·Ñ). â¢ Ð¤ÑÐ¾ÑÐ´ÐµÐ·Ð¾ÐºÑÐ¸Ð³Ð»ÑÐºÐ¾Ð·Ð° (Ð¤ÐÐ), Ð¾Ð±Ð»Ð°ÑÑÑ Ð¿ÑÐ¸Ð¼ÐµÐ½ÐµÐ½Ð¸Ñ Ð² Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½Ðµ. Ð Ð½Ð°ÑÑÐ¾ÑÑÐµÐµ Ð²ÑÐµÐ¼Ñ ÐÐ­Ð¢ ÑÐµÑÐ½Ð¾Ð»Ð¾Ð³Ð¸Ñ ÑÐ²Ð»ÑÐµÑÑÑ Ð¾Ð´Ð½Ð¾Ð¹ Ð¸Ð· Ð»Ð¸Ð´Ð¸ÑÑÑÑÐ¸Ñ Ð² Ð¾Ð±Ð»Ð°ÑÑÐ¸ Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½ÑÐºÐ¾Ð¹ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ¸. ÐÐ»Ñ Ð´Ð°Ð½Ð½Ð¾Ð¹ Ð¿ÑÐ¾ÑÐµÐ´ÑÑÑ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·ÑÑÑÑÑ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÐµ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ, ÑÐ¾Ð·Ð´Ð°Ð½Ð½ÑÐµ Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð². ÐÐ´Ð½Ð¸Ð¼ Ð¸Ð· ÑÐ°Ð¼ÑÑ ÑÐ¸ÑÐ¾ÐºÐ¾ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·ÑÐµÐ¼ÑÑÂ  ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð² ÑÐ²Ð»ÑÐµÑÑÑ 18F, Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ Ð½Ð° ÐµÐ³Ð¾ Ð¾ÑÐ½Ð¾Ð²Ðµ Ð¿ÑÐ¸Ð¼ÐµÐ½ÑÑÑÑÑ Ð¿ÑÐ¸ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐµ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ Ð¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð½Ð¸Ð¹ Ð² ÑÐµÐ»Ðµ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. Ð¡Ð¾Ð·Ð´Ð°Ð½Ð¸Ðµ ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ° ÑÐ²Ð»ÑÐµÑÑÑ ÑÐ»Ð¾Ð¶Ð½Ð¾Ð¹ Ð¼Ð½Ð¾Ð³Ð¾ÑÑÐ°Ð¿Ð½Ð¾Ð¹ Ð¿ÑÐ¾ÑÐµÐ´ÑÑÐ¾Ð¹, Ð²Ð¾ Ð²ÑÐµÐ¼Ñ ÐºÐ¾ÑÐ¾ÑÐ¾Ð¹ ÑÑÐ¸ÑÑÐ²Ð°ÑÑÑÑ ÐºÐ°Ðº ÑÐ´ÐµÑÐ½Ð¾-ÑÐ¸Ð·Ð¸ÑÐµÑÐºÐ¸Ðµ, ÑÐ°Ðº Ð¸ ÑÐ¸Ð¼Ð¸ÑÐµÑÐºÐ¸Ðµ ÑÐ°ÐºÑÐ¾ÑÑ. ÐÐ°Ð½Ð½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° ÑÐ»ÑÐ¶Ð¸Ñ Ð¾Ð±Ð·Ð¾ÑÐ¾Ð¼ Ð¿ÑÐ¾ÑÐµÑÑÐ° Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´ÑÑÐ²Ð° Ð Ð¤Ð, Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ ÑÐ°ÐºÑÐ¾ÑÐ¾Ð², Ð²Ð»Ð¸ÑÑÑÐ¸Ñ Ð½Ð° ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²Ð¾ ÑÐ¾Ð·Ð´Ð°Ð²Ð°ÐµÐ¼Ð¾Ð³Ð¾ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ°, Ð¾ÑÐ¾Ð±ÐµÐ½Ð½Ð¾ÑÑÐµÐ¹ Ð¿ÑÐ¾ÑÐµÑÑÐ° Ð½Ð°ÑÐ°Ð±Ð¾ÑÐºÐ¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð° Ð¸ ÑÐ¸Ð½ÑÐµÐ·Ð° Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ°, Ð¾ÑÐ½Ð¾Ð²ÑÐ²Ð°ÑÑÑ Ð½Ð° Ð»Ð¸ÑÐµÑÐ°ÑÑÑÐ½ÑÑ Ð¸ÑÑÐ¾ÑÐ½Ð¸ÐºÐ°Ñ.
description: In the qualification work on the topic âFeatures of the production of radiopharmaceuticals based on the radionuclide 18F using a cyclotronâ, the following questions were considered: â¢ Definition of radiopharmaceuticals and their relationship with radionuclides, classification and scope. â¢ Definition of PET, radionuclides for positron emission tomography. â¢ Definition of a cyclotron and the principle of its operation. â¢ Peculiarities of obtaining radionuclides using a cyclotron (for example, 18F). â¢ Stages of radiopharmaceutical production based on radionuclide 18F (on the example of fluorodeoxyglucose). â¢ Fluorodeoxyglucose (FDG), a field of application in medicine. Currently, PET technology is one of the leading in the field of medical diagnostics. For this procedure, various preparations created using radionuclides are used. One of the most widely used radionuclides is 18F; preparations based on it are used in the diagnosis of tumor formations in the human body. The creation of a radiopharmaceutical is a complex multi-stage procedure, during which both nuclear-physical and chemical factors are taken into account. This qualifying work serves as an overview of the radiopharmaceutical production process, a study of factors affecting the amount of the drug being created, the features of the process of radionuclide production and drug synthesis, based on literary sources.